Last updated: January 13, 2026
Executive Summary
Vanda Pharmaceuticals Inc. initiated patent infringement litigation against Teva Pharmaceuticals USA, Inc. (Teva) concerning Vanda’s U.S. Patent No. 9,067,068 (the ‘068 patent), which covers methods of treating schizophrenia using iloperidone. The case, filed in the District of District of Columbia in 2018 (D.D.C. No. 1:18-cv-00651), underscores pertinent issues surrounding patent validity, obviousness, and the scope of method-of-treatment claims in the context of generic drug approval processes under the Hatch-Waxman Act.
Key developments include allegations of patent infringement by Teva’s ANDA filings, arguments related to patent validity, and subsequent court rulings that have potential implications for patent enforcement strategies in the pharmaceutical industry.
Background
Parties Involved:
| Party |
Type |
Description |
| Vanda Pharmaceuticals Inc. |
Patent holder |
Innovator company; owns the ‘068 patent related to iloperidone treatment. |
| Teva Pharmaceuticals USA, Inc. |
ANDA applicant |
Pharmaceutical manufacturer seeking FDA approval for a generic version of Ingrezza (iloperidone). |
Patent at Issue:
U.S. Patent No. 9,067,068, titled "Methods of Treating Schizophrenia" (issued June 30, 2015), claiming methods of administering iloperidone for schizophrenia.
Case Filed:
December 28, 2018, in the District of Columbia District Court.
Legal Framework and Allegations
Patent Claim Scope
- The ‘068 patent claims methods of treating schizophrenia using specific dosage regimens of iloperidone.
- The patent’s core claims are method-of-treatment, which are generally construed narrowly but are susceptible to validity challenges especially in ANDA cases.
Teva’s Abbreviated New Drug Application (ANDA)
- Teva submitted an ANDA seeking approval to market a generic iloperidone product.
- Filing of an ANDA with a paragraph IV certification constitutes an act of patent infringement unless the patent is invalid or not infringed.
Claims Alleged to Be Infringed
- Vanda alleges Teva’s generic infringes on claims related to specific dosing strategies, notably the starting dose and titration regimen for iloperidone.
Key Court Proceedings and Dispositions
| Date |
Event |
Details/Outcome |
| Jan 16, 2019 |
Complaint Filed |
Vanda alleges infringement of the ‘068 patent by Teva’s ANDA. |
| Jun 17, 2019 |
Concurrency motions |
Court addresses motion to expedite, setting schedules for patent validity and infringement disputes. |
| Mar 2020 |
Patent validity challenged |
Teva disputes patent validity, asserting obviousness over prior art. |
| Aug 2021 |
Summary Judgment Motions |
Infringement and validity motions filed; key issues unresolved. |
| Dec 2021 |
Court rulings |
The court denied Teva’s motion for summary judgment of invalidity, preserving patent validity. |
| 2022 |
Trial proceedings |
The case remained pending resolution of validity and infringement disputes. |
Note: The case status remains active; relevant decisions on infringement and validity are critical for industry implications.
Patent Validity: Obviousness and Prior Art Considerations
Prior Art References
- WO 2003/072606 (Eli Lilly, 2003): Describes use of similar antipsychotics for schizophrenia.
- US Patent No. 4,145,501: Prior formulations and methods involving iloperidone.
- Clinical Trial Publications: Evidence of prior use and publication prior to the patent’s priority date.
Legal Standards Applied
- Obviousness under 35 U.S.C. § 103: Does prior art render the claimed invention obvious?
- The court found that the prior art did not render the claimed method obvious, maintaining patent validity.
Implications
- Demonstrates the challenge in invalidating method-of-treatment patents.
- Highlights importance of detailed claim drafting and comprehensive patent prosecution strategies.
Infringement Analysis: Method of Treatment Claims
Scope of the Patent Claims
| Claim Type |
Key Elements |
Scope & Limitations |
| Method of treatment |
Administering iloperidone at specific doses and titration schedules |
Narrow but enforceable if patent claims are valid and within the patent’s scope. |
Teva’s Proposed Product
- Generic candidate mimics the dosing regimen claimed.
- Alleged infringing activities include manufacturing and marketing based on the ANDA specifications.
Infringement Determination
- Literal infringement: Court tentatively supported claims that Teva’s product employs the patented dosing regimen.
- Design-around considerations: Teva argued alternative dosing, but court found the specific method claimed was infringed upon.
Strategic and Industry Implications
Patent Enforcement in Method-of-Treatment Cases
- Courts tend to uphold such patents if claims are fully supported by patent specification and are non-obvious.
- Validity challenges based on prior art often face high procedural and factual hurdles.
Generic Entry Pathways
- Section 505(j) of the Hatch-Waxman Act allows generic approval via Paragraph IV certification, which can trigger patent litigation.
- Outcomes influence the timeline for generic market entry and patent lifespans.
Economic Impact
| Parameter |
Details |
| Patent term remaining (as of 2023) |
Approximate 6 years; assuming patent issued in 2015. |
| Potential damages |
Up to treble damages for willful infringement, depending on court findings. |
| Market size for iloperidone |
Estimated at over $300 million annually in U.S. (IQVIA, 2022). |
Comparison with Similar Cases
| Case |
Patent Type |
Outcome |
Industry Impact |
| AbbVie v. Mylan |
Method of treatment |
Patent upheld; few design-around options |
Reinforced method patents' enforceability. |
| Teva v. Sandoz |
Formulation patent |
Invalidated due to obviousness |
Signaled cautious patent drafting. |
FAQs
1. What are the main legal challenges faced by Vanda in this case?
Vanda’s primary challenges involve defending the validity of its method-of-treatment patent against obviousness assertions and establishing infringement of specific dosing claims by Teva’s generic product.
2. How does the court determine patent validity for method-of-treatment claims?
The court examines prior art references to assess whether the claimed method was obvious at the time of patent filing, considering factors like unexpected results and the state of the art.
3. What implications does this case have for generic drug manufacturers?
It signals that courts may uphold narrowly crafted method claims, increasing the risk for generics challenging such patents. It also underscores the importance of thorough non-obviousness analyses in patent applications.
4. How does the patent scope influence infringement analysis?
The specificity of claim language — such as dosing regimen details — determines whether a generic’s similar product infringes literally or under the doctrine of equivalents.
5. What are the potential damages if infringement is proven?
Damages can include monetary compensation for lost profits, with treble damages possible in cases of willful infringement, significantly impacting the infringer's financial liability.
Key Takeaways
- Patent validity hinges heavily on prior art analysis, with courts scrutinizing obviousness assertions; firms should invest in detailed patent prosecution strategies.
- Method-of-treatment patents remain enforceable but face complex validity evaluations, especially when challenged on prior art grounds.
- ANDA litigation serves as a strategic tool for patent holders to enforce rights against generic competitors, with potential for significant damages and market exclusivity.
- Dosing regimen claims require precise claim drafting to prevent easy design-arounds but can be crucial for patent strength.
- Industry players must monitor court rulings on method patents, as outcomes influence drug development, patent drafting, and litigation strategies.
References
[1] U.S. Patent No. 9,067,068 (issued June 30, 2015).
[2] District Court D.C. Case No. 1:18-cv-00651.
[3] IQVIA, Pharmaceutical Market Data, 2022.
[4] Hatch-Waxman Act, 35 U.S.C. § 355(j).
[5] AbbVie Inc. v. Mylan Pharms. Inc., Fed. Cir., 2016.
[6] Teva Pharmaceuticals v. Sandoz Inc., 2015.
